Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Lymphoid 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Neoplasms 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1Carcinoid Tumor 1Adrenocortical Carcinoma 1

Interventions

romidepsin 1entrectinib 1amino-acid, glucose, and electrolyte solution 1alectinib 1TKM-080301 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Lactones 1Immunotherapy 1Fluorodeoxyglucose F18 1Everolimus 1Drug Therapy 1Depsipeptides 1Biological Therapy 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × TKM-080301 × Lymphoid × Clear all
NCT01262235 2019-01-16

A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients

Arbutus Biopharma Corporation

Phase 1/2 Completed
68 enrolled
EndocrineLymphoidNET

Carcinoid Tumor, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡